Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137719

Published: 2020

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Blood (2019) 133 (17): 1876–1887.

https://doi.org/10.1182/blood-2018-11-887067

Published: 2019

Includes: Supplemental data

Journal Articles

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Blood (2019) 133 (15): 1652–1663.

https://doi.org/10.1182/blood-2018-11-883710

Published: 2019

Includes: Supplemental data

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway

Coline Haxaire, Narine Hakobyan, Tania Pannellini, Camila Carballo, David McIlwain, Tak W. Mak, Scott Rodeo, Suchitra Acharya, Daniel Li, Jackie Szymonifka, Xiangqian Song, Sébastien Monette, Alok Srivastava, Jane E. Salmon, Carl P. Blobel

Blood (2018) 132 (10): 1064–1074.

https://doi.org/10.1182/blood-2017-12-820571

Published: 2018

Includes: Supplemental data

Journal Articles

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Joshua A. Hill, Daniel Li, Kevin A. Hay, Margaret L. Green, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Michael Boeckh, Cameron J. Turtle

Blood (2018) 131 (1): 121–130.

https://doi.org/10.1182/blood-2017-07-793760

Published: 2018

Includes: Supplemental data

Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 581.

https://doi.org/10.1182/blood.V130.Suppl_1.581.581

Published: 2017

Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 193.

https://doi.org/10.1182/blood.V130.Suppl_1.193.193

Published: 2017

Journal Articles

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Christina Swanson, PhD, Trevor Do, Samantha Merrigan, Shaparak Lonning, Kim Merriam, Joshua Prentiss, Janani Sridar, Claire L Sutherland, PhD, Benhuai Xie, PhD, Minh Pham, Daniel Li, PhD, Tina Albertson, MD, Howard M Stern, MDPhD, Sharon Moulis, PhD

Blood (2017) 130 (Supplement 1): 194.

https://doi.org/10.1182/blood.V130.Suppl_1.194.194

Published: 2017

Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD

Blood (2017) 130 (Supplement 1): 805.

https://doi.org/10.1182/blood.V130.Suppl_1.805.805

Published: 2017

Journal Articles

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Mark Heipel, BSc, Jeffrey Smith, BA, William Brown, MAS, Mandana Karimi, MSc, Benhuai Xie, PhD, Daniel Li, PhD, Tina Albertson, MD, Jacob Garcia, MD, Todd Devries, PhD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 2835.

https://doi.org/10.1182/blood.V130.Suppl_1.2835.2835

Published: 2017

Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 1552.

https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552

Published: 2017

Journal Articles

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Kevin A. Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W. Conrad Liles, Mark M. Wurfel, José A. López, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Sindhu Cherian, Xueyan Chen, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2017) 130 (21): 2295–2306.

https://doi.org/10.1182/blood-2017-06-793141

Published: 2017

Includes: Supplemental data

Journal Articles

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen

Blood (2017) 129 (25): 3322–3331.

https://doi.org/10.1182/blood-2017-02-769208

Published: 2017

Includes: Supplemental data

Journal Articles

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G Maloney, MD PhD

Blood (2016) 128 (22): 56.

https://doi.org/10.1182/blood.V128.22.56.56

Published: 2016

Journal Articles

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Cameron J Turtle, MBBS, PhD, Kevin A Hay, MDFRCPC, MSc, Gust Juliane, MD PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G. Maloney, MD PhD

Blood (2016) 128 (22): 1852.

https://doi.org/10.1182/blood.V128.22.1852.1852

Published: 2016

NARROW

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only